Effect of canagliflozin on N-terminal pro-brain natriuretic peptide in patients with type 2 diabetes and chronic heart failure according to baseline use of glucose-lowering agents

BACKGROUND: Sodium–glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of a deterioration in heart failure (HF) and mortality in patients with a broad range of cardiovascular risks. Recent guidelines recommend considering the use of SGLT2 inhibitors in patients with type 2 diabetes (T2D) and...

Descripción completa

Detalles Bibliográficos
Autores principales: Tanaka, Atsushi, Toyoda, Shigeru, Imai, Takumi, Shiina, Kazuki, Tomiyama, Hirofumi, Matsuzawa, Yasushi, Okumura, Takahiro, Kanzaki, Yumiko, Onishi, Katsuya, Kiyosue, Arihiro, Nishino, Masami, Sakata, Yasushi, Node, Koichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8417990/
https://www.ncbi.nlm.nih.gov/pubmed/34479543
http://dx.doi.org/10.1186/s12933-021-01369-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8417990/
https://www.ncbi.nlm.nih.gov/pubmed/34479543
http://dx.doi.org/10.1186/s12933-021-01369-5

Ejemplares similares